UBS analyst Trung Huynh lowered the firm’s price target on Bristol Myers (BMY) to $46 from $52 and keeps a Neutral rating on the shares. Bristol-Myers had a “solid” Q2 beat and raise, but uncertainty on ADEPT-2 is growing, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Options Volatility and Implied Earnings Moves Today, August 01, 2025
- Bristol Myers price target lowered to $47 from $51 at Citi
- Sell Rating for Bristol-Myers Squibb Due to Overly Optimistic Estimates and Clinical Trial Delays
- Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges
- Bristol-Myers Squibb Reports Strong Q2 2025 Results